Satsuma Pharmaceuticals Logo
US80405P1075
A2PQPD
STSA

Satsuma Pharmaceuticals

Loading quotes...

Forecast

Buy
  4
Hold
  9
Sell
  0

  • Satsuma Technologie announces auditor change after strategic review

    Satsuma Technologie said that Kreston Reeves LLP has resigned its appointment following discussions as part of a comprehensive strategic review and the appointment of a new leadership team in summer 2025. The board has launched a formal selection process for a new auditor to support the company’s growth plans. A statement from Kreston Reeves on its resignation will be circulated and published in accordance with the Companies Act 2006, and a new appointment will be announced in due course. » More on de.investing.com


  • Satsuma Technologie raises £163.6 million through successful convertible bond issuance

    Satsuma Technologie has raised £163.6 million by placing a second secured convertible bond, significantly surpassing its minimum target. The financing attracted prominent investors and allowed some to invest in Bitcoin instead of cash. The funds will be used for business expansion and to strengthen the company's Bitcoin-based treasury strategy. » More on de.investing.com


  • Tao Alpha becomes Satsuma Technology and adopts new ticker SATS.L

    Tao Alpha PLC is changing its name to Satsuma Technology PLC and adopting the new ticker symbol SATS.L on the London Stock Exchange. The rebranding is intended to highlight the company's focus on decentralized AI services and a Bitcoin-based treasury strategy, while existing shareholder rights remain unaffected. CEO Matthew Lodge emphasizes that this marks a step into a new phase of operational maturity. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2014, Satsuma Pharmaceuticals has already paid €0.29 in dividends. The last payout was in April 2014.

Financials

In the last year, Satsuma Pharmaceuticals had revenue of €0 and net profit of -€64.48M
(EUR) 2022
YoY
Revenue 0 -
Gross profit 0 -
Net profit -64.48M 43.02%
EBITDA -54.36M 22.13%

Fundamentals

Metric Value
Market capitalization
€31.39M
Number of shares
33.15M
52-week high/low
€6.95 - €0.51
Dividends No
Beta
0.10
P/E ratio
-0.51
PEG ratio
0.05
P/B ratio
-0.17
P/S ratio
0.00

Company profile

Satsuma Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige therapeutische Produkte für die akute Behandlung von Migräne entwickelt. Der führende Produktkandidat des Unternehmens ist STS101, eine Arzneimittel-Geräte-Kombination aus einer patentrechtlich geschützten Trockenpulverformulierung von Dihydroergotaminmesylat, die sich in SUMMIT-Phase-3-Wirksamkeitsstudien befindet und mit einem patentrechtlich geschützten, vorgefüllten Einweg- und Nasenspritzgerät selbst verabreicht werden kann. Satsuma Pharmaceuticals, Inc. wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.

Name
Satsuma Pharmaceuticals
CEO
John A. Kollins MBA
Headquarters South San Francisco, ca
USA
Website
Sector
Materials
Industry
Chemicals
IPO
09/13/2019
Employees 25

Ticker symbols

Exchange Symbol
NASDAQ
STSA
🍪

Parqet  uses cookies. Learn more